Inflammatory conditions, such as inflammatory bowel disease, have focused on IL-10 as a treatment but are yet to see clinical improvements due to challenges with drug stability, bioavailability, and the complexity of immune responses (49). Here, IL10 is linked to inflammatory bowel disease.